- Rituximab shows promise in a small case series of children with refractory childhood-onset lupus erythematosus panniculitis (LEP).
Why this matters
- LEP is a disfiguring condition, but large studies of specific therapies would be difficult to conduct because of its rarity.
- 3 patients were male (2 were brothers) and 1 was female, aged 18, 22, 7, and 8 years, respectively.
- All 4 had a “rapid and sustained” response to the rituximab therapy.
- The only adverse event was a minor infusion reaction in 1 patient.
- Retrospective observational case series, single tertiary-care clinic.
- Outcomes were a decrease in number and size of red, tender nodules (palpated or visually); reduction in facial atrophy; tolerability.
- Funding: None disclosed.
- A small case series at a single institution.